Ad.PEG-E1A + interferon gamma

Ad.PEG-E1A + interferon gamma is an **experimental cancer therapy** that combines an oncolytic adenovirus vector (Ad.PEG-E1A) with delivery of **interferon gamma**, typically via transgene expression[3]. The Ad.PEG-E1A component is a **replication-competent adenovirus** engineered to replicate preferentially in tumor cells using the PEG-3 promoter, enhancing selectivity for cancer cells while sparing normal tissue[3]. The vector additionally encodes **interferon gamma (IFN-γ)**, a pleiotropic immunomodulatory cytokine, enabling sustained local production within the tumor environment[3]. IFN-γ induces antitumoral immune responses by activating natural killer cells and stimulating cytotoxic T lymphocytes, as well as exerting direct effects such as **antiproliferation, apoptosis, and antiangiogenesis** on tumor cells[6]. This combination intends to maximize both direct oncolytic activity and immune-mediated clearance of cancer cells. Preclinical studies have shown **tumor regression and local immune activation** after intratumoral administration in animal cancer models[3]. The developer is primarily associated with research described by Sarkar et al[3].